SK Bioscience Licenses Novel RSV Monoclonal Antibody from Gates Medical Research Institute
核心洞察
SK bioscience (搜索) has secured exclusive worldwide rights to commercialize RSM01, a clinical-stage monoclonal antibody (搜索) designed to prevent RSV (搜索) infection in newborns and infants with a single dose.
The antibody demonstrated strong viral inhibition in preclinical studies and showed safety and tolerability in Phase 1a trials, with plans to advance to Phase 1b trials in infants.
The licensing agreement includes Global Access commitments to ensure affordable supply to low- and middle-income countries, where 97% of RSV (搜索)-related infant deaths occur.
SK bioscience (搜索) announced it has entered into a license agreement with the Gates Medical Research Institute (搜索) (Gates MRI (搜索)) to develop and commercialize RSM01, a clinical-stage monoclonal antibody (搜索) candidate for preventing respiratory syncytial virus (搜索) (RSV (搜索)) infection in infants. The South Korean biotech company secured exclusive worldwide commercialization rights for high-income countries, with non-exclusive supply arrangements for India and Gavi-eligible countries.
Addressing Critical Gaps in RSV Prevention
RSV (搜索) represents a significant global health burden, causing an estimated 100,000 deaths annually among infants under six months of age worldwide. Approximately 97% of these deaths occur in low- and middle-income countries, highlighting the unequal global distribution of RSV-related disease burden.
Current RSV (搜索) prevention options face significant limitations. Maternal immunization requires vaccination during a specific pregnancy window, potentially limiting coverage for some infants. Available preventive antibodies are high-cost interventions with access largely concentrated in high-income countries, leaving many newborns and young infants inadequately protected against RSV.
Novel Antibody Design and Clinical Promise
The RSV (搜索) preventive monoclonal antibody (搜索) candidate, engineered by Adimab (搜索) in collaboration with Gates MRI (搜索), is designed for administration to newborns and infants during their first RSV season. A single dose is intended to provide rapid and durable protection throughout an entire RSV season.
In preclinical studies, RSM01 demonstrated strong inhibition of viral infection and replication in both in vitro and in vivo models. Notably, the antibody showed activity against certain RSV (搜索) strains reported to have reduced susceptibility to currently available licensed products.
The candidate's clinical development has progressed through Phase 1a first-in-human studies conducted in healthy adults in the United States. The trial demonstrated that RSM01 was generally safe and well-tolerated, with data suggesting potential for sustained protection throughout the RSV (搜索) season following single administration.
Accelerated Development Timeline
Based on the positive Phase 1a findings, SK bioscience (搜索) plans to advance swiftly into Phase 1b clinical trials in infants to accelerate the monoclonal antibody (搜索)'s development. This represents a critical step toward validating the therapy's safety and efficacy in the target pediatric population.
Global Access and Manufacturing Strategy
The licensing agreement incorporates Global Access commitments aligned with Gates MRI (搜索)'s charitable mission to advance equitable access to lifesaving health technologies. SK bioscience (搜索) plans to develop large-scale manufacturing processes to enable affordable supply to low-resource settings, where RSV (搜索)-associated infant mortality remains high.
This dual approach reflects SK bioscience (搜索)'s strategy to balance commercial value generation in developed markets with public health impact in resource-limited settings. The company has maintained a long-standing commitment to global public health, having received Gates Foundation (搜索) grant funding since 2013 for affordable vaccine production and clinical development.
Market Dynamics and Future Outlook
Global demand for RSV (搜索) prevention continues to rise, with the market for RSV preventive antibodies projected to reach $4.5 billion by 2032, according to Evaluate Pharma. The World Health Organization's Global Market Study on RSV Immunization Products (2024) noted that demand for RSV antibodies could increase sharply depending on affordability and inclusion in national immunization programs.
"This newly in-licensed RSV (搜索) preventive monoclonal antibody (搜索) candidate is a strategic program that aligns public-health impact with commercial viability, and it will be a key priority for strengthening our portfolio competitiveness over the mid- to long-term," said Jaeyong Ahn, CEO of SK bioscience (搜索). "Going forward, we will continue to enhance our business capabilities and drive sustainable growth through technology-driven investment and expanded global partnerships."